NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
HEATHER J GOTHAM · EMORY UNIVERSITY · 2024 · $704,512 — Rates of risky alcohol and drug use and alcohol and substance use disorders (AUDs/SUDs) are highest among women during their reproductive years compared to other periods of the life course. AUDs and SUDs are associated with significant and lifelong behavioral, mental, physical, and sexual and reprod…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Bharti Khurana · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $170,705 — Project Abstract This project is focused on developing an automated clinical decision support tool for predicting Intimate Partner Violence (IPV) risk and severity based on historical imaging and clinical data. Despite the high prevalence and urgency of this critical public health issue, there is cu…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
James D Brien · UNIVERSITY OF PUERTO RICO MED SCIENCES · 2024 · $812,000 — SUMMARY/ABSTRACT Although more than four years have passed since the initial virus appearance, nowadays, most of the population has been vaccinated with multiple doses of mRNA-based vaccines and has endured multiple infection events. Still, SARS-CoV-2 continues to cause disproportionately higher mor…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Scott Dexter Boyd · STANFORD UNIVERSITY · 2024 · $939,222 — SUMMARY The Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) has remained true to its original goals as a member of the SeroNet consortium organized to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus in the Covid-19…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Jacek Skarbinski · KAISER FOUNDATION RESEARCH INSTITUTE · 2024 · $302,796 — Abstract Serologic testing for presence of SARS-CoV-2 antibodies is a critical tool for understanding the epidemiology and designing control strategies for the COVID-19 pandemic. Our understanding of the epidemiology of this pandemic is primarily derived from real-time data on the number of polymera…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
ANDREA L COX · JOHNS HOPKINS UNIVERSITY · 2024 · $759,945 — Johns Hopkins has broad expertise in the science of human health, with viral immunity, pathogenesis, epidemiology, biostatistics, and surveillance emerging as integral components of the multidisciplinary research mounted at Johns Hopkins during the current pandemic. We propose development of a Serol…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Rong Fan · YALE UNIVERSITY · 2024 · $107,220 — Summary The main goals of the Supplement Award are to (1) correlate immunoserological responses to early immune reactions in local tissue environment of the vaccine injection site in healthy donors, and (2) the compare between healthy controls and patients with hematological disorders or autoimmune …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Rachael Wolters · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $122,850 — Project Summary/Abstract Influenza causes an estimated 1 billion cases yearly, with severe cases leading to fatal bronchopneumonia, particularly in vulnerable populations. Influenza virions express two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), the latter of which is of…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
ELIZABETH A CAMPBELL · ROCKEFELLER UNIVERSITY · 2024 · $620,543 — Project Summary COVID-19, caused by the coronavirus SARS-CoV-2, continues to devastate the world. In less than a year, there have been more than 20 million cases with over 700,000 deaths. The viral RNA-dependent RNA polymerase (RdRp) is the central enzyme responsible for transcription and replicatio…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
ELIZABETH ANN FITZPATRICK · EMORY UNIVERSITY · 2024 · $645,603 — PROJECT SUMMARY/ABSTRACT COVID-19 was first identified in December 2019 in Wuhan, Hubei province, China, resulting in the ongoing 2019- 2020 pandemic. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2). Common symptoms of the disease include fever, dry cough, sho…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Erica L Eliason · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2024 · $248,988 — PROJECT SUMMARY/ABSTRACT Career Goal: My long-time career goal is to become an independent investigator studying the effects of health care policies on access and use of maternal and infant health care services among low-income populations. With additional skills in claims data, subject matter exper…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Sung Chun · BOSTON CHILDREN'S HOSPITAL · 2024 · $827,753 — Idiopathic Pulmonary Fibrosis (IPF) inflicts a significant healthcare burden and high rate of mortality in the U.S. Current treatment options can slow the rate of lung function decline, but the five-year survival remains low, therefore there is clear unmet medical needs for novel therapeutics. Here,…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
SAMUEL JEREMY PLEASURE · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $575,015 — PROJECT SUMMARY COVID-19 is associated with a growing number of peripheral and central nervous system complications. It has become clear that a subset of these syndromes, including acute necrotizing encephalopathy, steroid- responsive encephalitis and Guillain-Barré syndrome, are likely due to dire…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
KENNETH SEEDMAN KENDLER · VIRGINIA COMMONWEALTH UNIVERSITY · 2024 · $589,808 — Program Director/Principal Investigator: Kendler, Kenneth S This second competitive renewal seeks to continue our innovative and productive research program which seeks to understand the etiology of drug use disorders (DUD) utilizing data available on the entire population of Sweden of unparalleled …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Clifton W. Callaway · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $380,790 — The University of Pittsburgh site for the Strategies to Innovate Emergency Care Clinical Trials Network (SIREN) will continue its leadership as a Hub for recruiting participants into emergency care research. Advancements in acute treatment for time-sensitive and life-threatening conditions requires …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Ousseny Zerbo · KAISER FOUNDATION RESEARCH INSTITUTE · 2024 · $539,708 — Abstract: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) which emerged in December 2019 and has since led to an unprecedented global pandemic with high morbidity and mortality. Current authorized vaccines against SARS-CoV-2 demo…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Jeffrey Parsonnet · DARTMOUTH-HITCHCOCK CLINIC · 2024 · $150,000 — The purpose of this project is to address health disparities in the care of patients with post-acute COVID syndrome (PACS) due to the rural nature of northern New England and its shortage of medical services. We will develop useful, understandable and relatable information for patients and providers…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Vishnu Mohan · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $666,827 — Project Summary Over the past decade, there has been a growing epidemic of physician burnout, driven most notably, by Electronic Health Records (EHR), and the increasing amount of time providers spend on them. A number of solutions have been developed to untether the provider from the EHR. Prior to…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Margaret Gorvine · UNIV OF ARKANSAS FOR MED SCIS · 2024 · $132,063 — PROJECT SUMMARY The purpose of this K01 Mentored Research Scientist Career Development award is to support Dr. Margaret Gorvine's current trajectory toward independent investigator status—via achieving the study aims and training goals to extend innovative research in the arenas of implementation s…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Radha Korupolu · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2024 · $225,005 — Project Summary: The prevalence of debilitating chronic pain in people with spinal cord injury (SCI) ranges from 65-85%. Chronic pain after SCI contributes to anxiety, depression and diminishes the health-related quality of life (QOL). Pharmacological agents such as opioids are the primary therapeut…